Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166439 · ClinicalTrials.gov registry record · Phase 2
Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00166439: Completed Phase 2 study, sponsored by Academic and Community Cancer Research United.
NCT00166439 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00166439, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
Primary Outcome
The overall response rate is defined as the percentage of patients who achieve a response after two cycles of oxaliplatin with rituximab, cytarabine, and dexamethasone (ROAD). A response was considered a Complete Response (CR) or Partial Response (PR) as defined by the NCI Sponsored International Working Group (IWG). CR: Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present before therapy, and normaliza
Interventions
- DRUG Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-03 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
What the finished NCT00166439 record still lists
NCT00166439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) is the first listed.
NCT00166439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00166439 about?
NCT00166439 is a clinical study titled "Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma". The goals of this protocol are to determine the effect of oxaliplatin, cytosine arabinoside, and dexamethasone with Rituxan (ROAD) as treatment for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL).
What is the current status of trial NCT00166439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-03. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00166439?
The interventions under investigation include: Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) (DRUG).
Who is sponsoring clinical trial NCT00166439?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00166439's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia